Intrexon Corp (OQ:XON)

Business Focus: Biotechnology & Medical Research

May 29, 2019 04:00 am ET
Fibrocell Receives FDA Regenerative Medicine Advanced Therapy Designation for FCX-007 Gene Therapy for the Treatment of RDEB
Fibrocell Science, Inc. (Nasdaq: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted the...
May 28, 2019 03:30 am ET
Intrexon to Participate in 2019 BIO International Convention
GERMANTOWN, Md., May 28, 2019 /PRNewswire/ -- Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced the Company and its subsidiaries will participate in the 2019 BIO International Convention June 3-6th in Philadelphia.  ...
May 13, 2019 03:30 am ET
Intrexon to Present at the Bank of America Merrill Lynch 2019 Healthcare Conference
GERMANTOWN, Md., May 13, 2019 /PRNewswire/ -- Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced Randal J. Kirk, Chairman and Chief Executive Officer, will present at the Bank of America Merrill Lynch 2019 Healthcare Conference in Las Vegas on Wednesday, May 15th, at 3:40 p.m. Pacific Time. Mr. Kirk will focus on Intrexon Health's development of targeted, controllable, multigenic therapeutics for the treatment of complex diseases and unmet medical needs, highlighting the the...
May 09, 2019 12:10 pm ET
Intrexon Reports First Quarter 2019 Financial Results
GERMANTOWN, Md., May 9, 2019 /PRNewswire/ -- Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced its first quarter financial results for 2019. ...
May 02, 2019 12:30 pm ET
AquaBounty Technologies, Inc. Announces Results for the Quarter Ended March 31, 2019, and Company Update
AquaBounty Technologies, Inc. (NASDAQ: AQB) (“AquaBounty” or the “Company”), a biotechnology company focused on enhancing productivity in the aquaculture market and a subsidiary of Intrexon Corporation (NASDAQ: XON), announces the Company’s...
May 02, 2019 12:05 pm ET
Intrexon to Release First Quarter 2019 Financial Results on May 9th
GERMANTOWN, Md., May 2, 2019 /PRNewswire/ -- Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced it will release first quarter 2019 financial results after the market closes on Thursday, May 9th, 2019.  The Company will not host a conference call associated with the earnings release....
Apr 29, 2019 03:30 am ET
Intrexon and Xogenex Present at American Society of Gene and Cell Therapy Annual Meeting
GERMANTOWN, Md., April 29, 2019 /PRNewswire/ -- Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, and its majority owned Intrexon Health subsidiary Xogenex, today announced that four abstracts will be presented as posters at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, which will be held April 29 - May 2, 2019, at the Washington Hilton in Washington, D.C. ...
Apr 25, 2019 12:05 pm ET
Precigen Opens Gene and Cell Therapy Manufacturing Facility in Germantown, Maryland
GERMANTOWN, Md., April 25, 2019 /PRNewswire/ -- Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation (NASDAQ: XON) and a clinical stage biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients, today announced the official opening of its new manufacturing facility. Precigen commenced the build-out of the nearly 5,000 square foot manufacturing facility in 2018 to support gene therapy manufacturing. The good manufacturing practices (GMP) facility was designed with agility and control in mind, focusing on r...
Apr 17, 2019 12:45 pm ET
AquaBounty Technologies, Inc. Announces Exercise of Option to Purchase Additional Shares
AquaBounty Technologies, Inc. (Nasdaq: AQB) (“AquaBounty” or the “Company”), a biotechnology company focused on enhancing productivity in the aquaculture market and a subsidiary of Intrexon Corporation (Nasdaq: XON), today announces the closing of...
Apr 16, 2019 03:30 am ET
Oxitec Signs New Multi-year Development Agreement to Apply 2nd Generation Technology to Control Soybean Looper
OXFORD, England, April 16, 2019 /PRNewswire/ -- Oxitec Ltd., a UK-based biotechnology company that pioneered the use of biologically-engineered insects to control disease-spreading mosquitoes and crop-destroying agricultural pests and a wholly-owned subsidiary of Intrexon (NASDAQ: XON), has announced the signing of a new multi-year development agreement with a collaborator to develop a self-limiting soybean looper (Chrysodeixis includens) to suppress this damaging agricultural pest that is found throughout the Americas. ...
Apr 15, 2019 02:30 am ET
Fibrocell Announces Collaboration with Castle Creek Pharmaceuticals to Develop and Commercialize FCX-007 Gene Therapy
Fibrocell Science, Inc. (Nasdaq: FCSC), a cell and gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced the completion of a collaboration agreement with Castle...
Apr 10, 2019 03:30 am ET
Intrexon to Highlight Microbial Cannabinoid Production Platform at the Paradigm Capital Biosynthesis Conference
GERMANTOWN, Md., April 10, 2019 /PRNewswire/ -- Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced Thomas D. Reed, PhD, Founder and Chief Science Officer, will present at the Paradigm Capital Biosynthesis Conference on April 15, 2019 in Toronto. This inaugural conference will focus on exploring the most disruptive technology in the cannabis industry, bringing together investors and companies interested in the efficient, clean, and scalable production of cannabinoids. ...
Apr 09, 2019 12:00 pm ET
AquaBounty Technologies, Inc. Announces Closing of Public Offering of Common Stock
AquaBounty Technologies, Inc. (Nasdaq: AQB) (“AquaBounty” or the “Company”), a biotechnology company focused on enhancing productivity in the aquaculture market and a subsidiary of Intrexon Corporation (Nasdaq: XON), today announces the closing of...
Apr 09, 2019 03:30 am ET
Oxitec Advances Self-Limiting Fall Armyworm Control Solution to Next Phase of Development
OXFORD, England, April 9, 2019 /PRNewswire/ -- Oxitec Ltd., a wholly-owned subsidiary of Intrexon (NASDAQ: XON), today announced it has entered into a second agreement with a collaborator to advance the next phase of development of its self-limiting fall armyworm control solution. This announcement comes after the successful conclusion of an initial three-year research and development collaboration that funded the early development of the self-limiting fall armyworm strain. Under the new agreement, the collaboration will focus on scale-up of the technology and the launch of initial field tri...
Apr 04, 2019 05:55 pm ET
AquaBounty Technologies, Inc. Announces Pricing of $5.75 Million Public Offering of Common Stock
AquaBounty Technologies, Inc. (Nasdaq: AQB) (“AquaBounty” or the “Company”), a biotechnology company focused on enhancing productivity in the aquaculture market and a subsidiary of Intrexon Corporation (Nasdaq: XON), today announced the pricing of...
Apr 04, 2019 12:08 pm ET
AquaBounty Technologies, Inc. Announces Proposed Public Offering of Common Stock
AquaBounty Technologies, Inc. (Nasdaq: AQB) (“AquaBounty” or the “Company”), a biotechnology company focused on enhancing productivity in the aquaculture market and a majority-owned subsidiary of Intrexon Corporation (Nasdaq: XON), today announced...
Apr 03, 2019 03:30 am ET
Intrexon Intensifies Focus on Healthcare, Forms Two Units and Streamlines Management
GERMANTOWN, Md., April 3, 2019 /PRNewswire/ -- Intrexon Corporation (NASDAQ: XON), announced today that it will align its operations into two units, Intrexon Health and Intrexon Bioengineering, to better deploy resources, realize inherent synergies and position the company for growth with a core focus on healthcare.  Intrexon Health, will be led by Randal J. Kirk, Chairman and Chief Executive Officer of Intrexon while Intrexon Bioengineering will be led by LTG (Ret.) Thomas Bostick, PhD, PE, Chief Operating Officer of Intrexon who in addition will assume the title of President, Intrexon Bioe...
Apr 02, 2019 03:00 am ET
AquaBounty Technologies, Inc. Environment and Climate Change Canada Approves Rollo Bay Facility for Commercial Production of AquAdvantage Salmon
AquaBounty Technologies, Inc. (NASDAQ: AQB) (“AquaBounty” or the “Company”), a biotechnology company focused on enhancing productivity in the aquaculture market and a majority-owned subsidiary of Intrexon Corporation (NASDAQ: XON), announces that...
Mar 21, 2019 12:01 pm ET
AquaBounty Technologies, Inc. Announces Closing of Public Offering of Common Stock
AquaBounty Technologies, Inc. (Nasdaq: AQB) (“AquaBounty” or the “Company”), a biotechnology company focused on enhancing productivity in the aquaculture market and a majority-owned subsidiary of Intrexon Corporation (Nasdaq: XON), today announces...
Mar 19, 2019 02:00 am ET
AquaBounty Technologies, Inc. Announces Proposed Public Offering of Common Stock
AquaBounty Technologies, Inc. (Nasdaq: AQB) (“AquaBounty” or the “Company”), a biotechnology company focused on enhancing productivity in the aquaculture market and a majority-owned subsidiary of Intrexon Corporation (Nasdaq: XON), today announced...
Mar 18, 2019 12:00 pm ET
AquaBounty Technologies, Inc. Announces Proposed Public Offering of Common Stock
AquaBounty Technologies, Inc. (Nasdaq: AQB) (“AquaBounty” or the “Company”), a biotechnology company focused on enhancing productivity in the aquaculture market and a majority-owned subsidiary of Intrexon Corporation (Nasdaq: XON), today announced...
Mar 08, 2019 10:19 am ET
AquaBounty Technologies, Inc. - FDA Lifts Import Alert on AquAdvantage Salmon
AquaBounty Technologies, Inc. (NASDAQ: AQB) (“AquaBounty” or the “Company”), a biotechnology company focused on enhancing productivity in the aquaculture market and a majority-owned subsidiary of Intrexon Corporation (NASDAQ: XON), announces the...
Mar 07, 2019 12:00 pm ET
AquaBounty Technologies, Inc. Results for the year ended December 31, 2018
AquaBounty Technologies, Inc. (NASDAQ: AQB) (“AquaBounty” or the “Company”), a biotechnology company focused on enhancing productivity in the aquaculture market and a majority-owned subsidiary of Intrexon Corporation (NASDAQ: XON), announces the...
Mar 05, 2019 02:45 am ET
Market Trends Toward New Normal in Ritchie Bros. Auctioneers, Empire State Realty Trust, Synergy Resources, IQVIA, Intrexon, and Denbury Resources — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Ritchie Bros. Auctioneers Incorporated (NYSE:RBA), Empire State Realty...
Mar 04, 2019 01:30 am ET
Intrexon and Surterra Wellness to Collaborate on Botticelli™ Next Generation Plant Propagation for Cannabis Cultivation
DAVIS, Calif., March 4, 2019 /PRNewswire/ -- Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced a strategic licensing agreement with Surterra Wellness (Surterra), one of the fastest growing health and wellness companies in the United States (US), to utilize Intrexon's Botticelli™ next generation plant propagation platform for the production of Surterra's specific cannabis cultivars for the Florida market. The collaboration agreement includes two-stages: 1) an optimization ph...
Feb 28, 2019 10:15 am ET
Intrexon Reports 2018 Fourth Quarter and Year End Financial Results
GERMANTOWN, Md., Feb. 28, 2019 /PRNewswire/ -- Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced its fourth quarter and full year financial results for 2018. ...
Feb 27, 2019 01:30 am ET
Intrexon to Showcase Differentiated Methane Bioconversion Platform at Upcoming Petroleum Industry Events
GERMANTOWN, Md., Feb. 27, 2019 /PRNewswire/ -- Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced Robert Walsh, senior vice president, Energy and Fine Chemicals Platforms, will participate in a panel on "What to watch out for in downstream – how and where the industry's landscape might change in the future" at the Energy Institute's International Petroleum Week in London on February 28, 2019. Mr. Walsh will also present in the Technology Seminar session at the IHS Markit Wor...
Feb 21, 2019 01:30 am ET
Intrexon to Announce Fourth Quarter 2018 Financial Results on February 28th
GERMANTOWN, Md., Feb. 21, 2019 /PRNewswire/ -- Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced it will release fourth quarter 2018 financial results after the market closes on Thursday, February 28th, 2019.  The Company will host a conference call that day at 5:30 PM ET to discuss the results and provide a general business update....
Feb 20, 2019 03:00 am ET
Intrexon's Subsidiary Precigen to Present at the SVB Leerink 8th Annual Global Healthcare Conference
GERMANTOWN, Md., Feb. 20, 2019 /PRNewswire/ -- Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, and its wholly-owned subsidiary Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients, today announced their presentation at the SVB Leerink 8th Annual Global Healthcare Conference in New York. Helen Sabzevari, PhD, president of Precigen, will present on Thursday, February 28, 2019 at 11:30 am Easte...
Feb 14, 2019 03:20 am ET
Consolidated Research: 2019 Summary Expectations for Sabre, Groupon, Intrexon, Comfort Systems, O'Reilly Automotive, and Ellington Financial — Fundamental Analysis, Key Performance Indications
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Sabre Corporation (NASDAQ:SABR), Groupon, Inc. (NASDAQ:GRPN), Intrexon...
Feb 11, 2019 01:30 am ET
Precigen Announces Clearance of IND to Initiate Phase 1 Study for First-in-Class PRGN-3005 UltraCAR-T™ to Treat Advanced Stage Platinum Resistant Ovarian Cancer Patients
GERMANTOWN, Md., Feb. 11, 2019 /PRNewswire/ -- Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation (NASDAQ: XON) and a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients, today announced that the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for Precigen's PRGN-3005, a first-in-class investigational therapy using autologous chimeric antigen receptor T (CAR-T) cells to treat advanced-stage platinum-resistant ovarian cancer patients. ...
Jan 15, 2019 01:30 am ET
Intrexon Partners with Next Green Wave to Advance Intrexon's Botticelli™ Next Generation Plant Propagation Platform into Development for Cannabis
DAVIS, Calif. and COALINGA, Calif., Jan. 15, 2019 /PRNewswire/ -- Intrexon Corporation (NASDAQ: XON) ("Intrexon"), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, and Next Green Wave Holdings Inc. (CSE:NGW) (OTCQB:NXGWF) ("Next Green Wave") are pleased to announce they have entered into a strategic licensing agreement to utilize Intrexon's Botticelli™ next generation plant propagation platform to enable rapid production of Next Green Wave's proprietary cannabis cultivars for the California market. The collaborative work co...
Jan 08, 2019 03:00 am ET
Investing in a New Age of Cannabinoid Production for Cost Efficiency and Scalability
Investorideas.com, a leading investor news resource covering hemp and cannabis stocks releases a snapshot of companies investing in new methods of cannabinoid production to meet the growing demands of the future According to Research and Markets,...
Jan 02, 2019 01:30 am ET
Intrexon Announces Presentations at Upcoming Investor Conferences
GERMANTOWN, Md., Jan. 2, 2019 /PRNewswire/ -- Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced that the company and its subsidiaries will present at upcoming investor conferences in San Francisco....
Dec 31, 2018 01:30 am ET
Precigen to Debut Portfolio at Investor Event during the 37th Annual J.P. Morgan Healthcare Conference
GERMANTOWN, Md., Dec. 31, 2018 /PRNewswire/ -- Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation (NASDAQ: XON) and a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients, today announced that the company will hold an investor event on Monday, January 7, 2019 during the 37th Annual J.P. Morgan Healthcare Conference in San Francisco. Helen Sabzevari, PhD, President, Precigen, will be presenting at the event....
Dec 24, 2018 01:30 am ET
Precigen to Host Conference Call to Provide Business Updates
GERMANTOWN, Md., Dec. 24, 2018 /PRNewswire/ -- Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation (NASDAQ: XON), and a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients, today announced that the company will host a conference call on Wednesday, December 26, at 8:30 AM ET to provide business updates, including an overview of Precigen's recent transition from an exclusive channel collaboration model to an agile R&D engine for greater focus, full developmental control and acceleration of its co...
Dec 21, 2018 06:35 am ET
Precigen Announces Clearance of IND to Initiate Phase 1/1b Study for First-in-Class PRGN-3006 UltraCAR-T™ Therapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) and Higher Risk M
GERMANTOWN, Md., Dec. 21, 2018 /PRNewswire/ -- Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation (NASDAQ: XON), and a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients, today announced that the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for PRGN-3006, a first-in-class investigational therapy using Precigen's UltraCAR-T™ platform. PRGN-3006 UltraCAR-T is an autologous chimeric antigen receptor T-cell (CAR-T) therapy for treatment of patients ...
Dec 21, 2018 01:30 am ET
Exemplar Genetics and Mayo Clinic Launch Joint Venture Focused on Development of Human Liver Cells to Advance Medical Research
SIOUX CENTER, Iowa, Dec. 21, 2018 /PRNewswire/ -- Exemplar Genetics, a subsidiary of Intrexon Corporation (NASDAQ: XON) and market leader in the development of genetically engineered miniswine as models of human disease, and Mayo Clinic have launched a joint venture focused on the development of a high quality source of human liver cells or hepatocytes (HHCs). The new company, Cytotheryx, headquartered in Rochester, Minnesota, will leverage the expertise and experience of Exemplar Genetics with the capabilities of Mayo Clinic's researchers to deliver this much-needed resource. ...
Dec 20, 2018 10:23 am ET
AquaBounty Technologies, Inc.: Issuance of USDA labeling rule
AquaBounty Technologies, Inc. (NASDAQ: AQB) (“AquaBounty” or the “Company”), a biotechnology company focused on enhancing productivity in the aquaculture market and a majority-owned subsidiary of Intrexon Corporation (NASDAQ: XON), is pleased to...
Dec 20, 2018 01:30 am ET
Intrexon and Merck KGaA, Darmstadt, Germany, Announce Agreement Realizing Precigen's Vision for Full Developmental Autonomy of its CAR-T Program
GERMANTOWN, Md., Dec. 20, 2018 /PRNewswire/ -- Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, and its wholly-owned subsidiary Precigen, a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients, today announced Intrexon has assumed its agreement with Merck KGaA, Darmstadt, Germany, a leading science and technology company, through its wholly-owned subsidiary Ares Trading, for the development of Chimeric Antigen...
Dec 18, 2018 01:30 am ET
Intrexon and AquaBounty Receive Regulatory Exemption in Development of Gene Edited Tilapia for More Sustainable Production
GERMANTOWN, Md. and MAYNARD, Mass., Dec. 18, 2018 /PRNewswire/ -- Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, and AquaBounty Technologies, Inc. (NASDAQ: AQB), a biotechnology company focused on enhancing productivity in the aquaculture market and a majority-owned subsidiary of Intrexon, announced that their jointly developed gene edited line of tilapia, FLT 01, is exempt from GM regulation according to Argentina's National Advisory Commission on Agricultural Biotechnology (CONABIA). ...
Nov 30, 2018 02:35 am ET
New Research: Key Drivers of Growth for Intrexon, Graham, The Walt Disney, Toyota Motor, Atlas Air Worldwide, and SITO Mobile — Factors of Influence, Major Initiatives and Sustained Production
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Intrexon Corporation (NASDAQ:XON), Graham Holdings Company (NYSE:GHC), The...
Nov 28, 2018 02:30 am ET
AquaBounty appoints Sylvia Wulf as Chief Executive Officer
AquaBounty Technologies, Inc. (NASDAQ: AQB) (“AquaBounty” or the “Company”), a biotechnology company focused on enhancing productivity in the aquaculture market and a majority-owned subsidiary of Intrexon Corporation (NASDAQ: XON), is pleased to...
Nov 28, 2018 01:30 am ET
Oxitec Transitioning Friendly™ Self-limiting Mosquitoes to 2nd Generation Technology Platform, Paving Way to New Scalability, Performance and Cost Breakthroughs
OXFORD, England, Nov. 28, 2018 /PRNewswire/ -- Oxitec, Ltd, a UK-based biotechnology company that pioneered the use of biologically-engineered insects for control of disease-spreading Aedes aegypti mosquitoes and crop-destroying agricultural pests, announced today it will be transitioning from its 1st generation self-limiting Friendly™ Aedes aegypti mosquito (also known as "OX513A") to a new Friendly™ Aedes mosquito ("OX5034") that uses Oxitec's 2nd generation technology, allowing the company to focus on advancing its entire mosquito and crop pest portfolios using this next-generation pl...
Nov 08, 2018 10:10 am ET
Intrexon Announces Third Quarter 2018 Financial Results
GERMANTOWN, Md., Nov. 8, 2018 /PRNewswire/ -- Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced its third quarter financial results for 2018. ...
Nov 02, 2018 03:30 am ET
AquaBounty Technologies, Inc. Results for the quarter and nine months ended September 30, 2018
AquaBounty Technologies, Inc. (NASDAQ: AQB) (“AquaBounty” or the “Company”), a biotechnology company focused on enhancing productivity in the aquaculture market and a majority-owned subsidiary of Intrexon Corporation (NASDAQ: XON), announces the...
Nov 01, 2018 03:30 am ET
Intrexon to Announce Third Quarter 2018 Financial Results on November 8th
GERMANTOWN, Md., Nov. 1, 2018 /PRNewswire/ -- Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced it will release third quarter 2018 financial results after the market closes on Thursday, November 8th, 2018.  The Company will host a conference call that day at 5:30 PM ET to discuss the results and provide a general business update....
Oct 29, 2018 01:14 pm ET
Bragar Eagel & Squire, P.C. is Investigating Intrexon Corporation (XON) on Behalf of Stockholders and Encourages XON Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating potential claims against Intrexon Corporation (NASDAQ: XON).  Our investigation concerns whether Intrexon has violated the federal securities laws and/or engaged in other unlawful business practices. On...
Oct 29, 2018 03:30 am ET
ActoBio Therapeutics™ Doses First Patient in Phase Ib/IIa Clinical Study of AG019 for the Treatment of Type 1 Diabetes
GHENT, Belgium, Oct. 29, 2018 /PRNewswire/ -- ActoBio Therapeutics, Inc., a wholly owned subsidiary of Intrexon Corporation (NASDAQ: XON) and innovative clinical-stage biotechnology company focused on a new class of microbe-based therapeutic agents, and Intrexon T1D Partners LLC, have announced that the first patient has been dosed in the Company's Phase Ib/IIa clinical trial for the treatment of early onset type 1 diabetes (T1D). ActoBiotics® AG019 is a therapeutic agent designed to induce immune tolerance in T1D, a disease with no approved disease-modifying treatment, which is currently ma...
Oct 24, 2018 03:30 am ET
Intrexon Announces the Formation of Bioinformatics Hub in Munich
GERMANTOWN, Md., Oct. 24, 2018 /PRNewswire/ -- Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced the formation of Intrexon Bioinformatics Germany GmbH, a Munich-based bioinformatics company.  Now a part of IBG, the Munich-based group of bioinformatics industry leaders have developed software tools focused on mapping genomic, transcriptomic, and epigenomic function in eukaryotic microbes and multicellular organisms employing diverse experimental inputs (microarray, ChipSeq, ...
Oct 23, 2018 04:40 am ET
Report: Exploring Fundamental Drivers Behind Q2, Badger Meter, Tiffany, Walgreens Boots Alliance, Intrexon, and Denali Therapeutics — New Horizons, Emerging Trends, and Upcoming Developments
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Q2 Holdings, Inc. (NYSE:QTWO), Badger Meter, Inc. (NYSE:BMI), Tiffany ...
Oct 18, 2018 04:43 am ET
Oct 16, 2018 01:28 pm ET
AquaBounty receives construction loan to support development efforts at its Rollo Bay property
AquaBounty Technologies, Inc. (NASDAQ: AQB) (“AquaBounty” or the “Company”), a biotechnology company focused on enhancing productivity in the aquaculture market and a majority-owned subsidiary of Intrexon Corporation (NASDAQ: XON), announces that...
Oct 16, 2018 12:56 pm ET
INVESTIGATION UPDATE for XON, APOG and ATASY: Levi & Korsinsky, LLP Reminds Investors of Investigations on Behalf of Shareholders
Levi Korsinsky, LLP announces that investigations have commenced on behalf of shareholders of the following publicly-traded companies. Intrexon Corporation (NASDAQGS: XON) Levi Korsinsky announces it has commenced an investigation of Intrexon...
Oct 12, 2018 03:38 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intrexon Corporation - XON
Pomerantz LLP is investigating claims on behalf of investors of Intrexon Corporation (“Intrexon” or the “Company”) (NASDAQ: XON).   Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980....
Oct 09, 2018 03:00 am ET
Ziopharm and Precigen Redefine Relationships, Announce New License Agreement
Ziopharm Oncology, Inc. (Nasdaq: ZIOP) and Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation (Nasdaq: XON), today announced a new definitive license agreement to replace all existing agreements between the companies that will...
Sep 25, 2018 03:30 am ET
Ziopharm Oncology to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference
Ziopharm Oncology, Inc. (Nasdaq:ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the Cantor Fitzgerald 2018 Global Healthcare Conference in New York on Tuesday, Oct. 2, at 2:15 p.m. ET. To access a...
Sep 24, 2018 03:30 am ET
Intrexon Announces Advances in Production of Medical Cannabis
BUDAPEST, Hungary, Sept. 24, 2018 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced advances in the development of its microbial platform to produce cannabinoids for medical uses.  Through Intrexon's proprietary technologies, the Company has engineered a yeast strain to produce low-cost, robust and consistent cannabinoid outputs via fermentation.  This process utilizing microbes has potential to provide greater supply-chain security, and avoids the resource-in...
Sep 17, 2018 06:10 am ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Intrexon Corporation (XON)
NEW YORK, Sept. 17, 2018 /PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Intrexon Corporation ("Intrexon" or the "Company") (NYSE: XON). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/xon. ...
Sep 14, 2018 03:16 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intrexon Corporation - XON
NEW YORK, Sept. 14, 2018 /CNW/ -- Pomerantz LLP is investigating claims on behalf of investors of Intrexon Corporation ("Intrexon" or the "Company") (NYSE: XON).   Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980....
Sep 14, 2018 03:16 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intrexon Corporation - XON
NEW YORK, Sept. 14, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Intrexon Corporation ("Intrexon" or the "Company") (NYSE: XON).   Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980....
Sep 14, 2018 09:53 am ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Intrexon Corporation and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Intrexon Corporation (“Intrexon” or “the Company”) (NYSE:
Sep 14, 2018 06:14 am ET
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Intrexon Corporation – XON
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Intrexon Corporation (NYSE: XON) resulting from allegations that Intrexon may have issued materially misleading business information to the investing public.
Sep 13, 2018 02:12 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Intrexon Corporation
Levi Korsinsky announces it has commenced an investigation of Intrexon Corporation (“Intrexon” or “the Company”) (NYSE: XON) concerning possible violations of federal securities laws. On August 9, 2018, Intrexon filed an 8-K announcing that it...
Sep 12, 2018 02:30 am ET
Intrexon Announces Transfer of Stock Listing to Nasdaq
GERMANTOWN, Md., Sept. 12, 2018 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced that it is transferring its stock exchange listing from the New York Stock Exchange (NYSE) to the Nasdaq Global Select Market (Nasdaq).  Intrexon will retain the "XON" ticker with trading on the Nasdaq exchange expected to begin on September 25, 2018.  ...
Sep 10, 2018 11:30 am ET
Black Soldier Fly Larvae Ingredients Receive FDA Recommendation for Poultry Diets
YELLOW SPRINGS, Ohio, Sept. 10, 2018 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has recommended amendment of the Association of American Feed Control Officials (AAFCO) ingredient definition of dried black soldier fly larvae (BSFL) to include feeding to poultry.  The approval of BSFL for use in poultry feed expands the potential for this ingredient as a more sustainable source of protein and enables a nutritious, natural feed ingredient for poultry diets. ...
Sep 04, 2018 03:30 am ET
Ziopharm Oncology Announces Scott Braunstein, M.D., Operating Partner at Aisling Capital, Nominated to Board of Directors
Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today announced that its Board of Directors has nominated Scott Braunstein, M.D., an Operating Partner at Aisling Capital, a leading healthcare investment firm, for election to the Board of Directors at the...
Aug 14, 2018 03:35 am ET
Research Report Identifies Acushnet, Capitol Federal Financial, Laredo Petroleum, Intrexon, Corning, and Idera Pharmaceuticals with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Acushnet Holdings Corp. (NYSE:GOLF), Capitol Federal Financial...
Aug 09, 2018 12:57 pm ET
Intrexon Business Update and Conference Call
GERMANTOWN, Md., Aug. 9, 2018 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, will host a call today to provide a general update and highlight recent business developments, as well as provide select preliminary and unaudited second quarter results.  ...
Aug 07, 2018 03:30 am ET
Ziopharm Oncology Announces Changes to its Board of Directors
Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today announced changes to the Company’s Board of Directors. Scott Tarriff, a member of the Board since 2015, has been elected to serve as Lead Director, succeeding Sir Murray Brennan, M.D. Both Sir Dr. Brennan...
Aug 07, 2018 03:00 am ET
AquaBounty Technologies, Inc. Results for the quarter and six months ended June 30, 2018
AquaBounty Technologies, Inc. (NASDAQ:AQB) (“AquaBounty” or the “Company”), a biotechnology company focused on enhancing productivity in the aquaculture market and a majority-owned subsidiary of Intrexon Corporation (NYSE: XON), announces the...
Aug 03, 2018 03:30 am ET
Intrexon to Present at the Jefferies 2018 Global Industrials Conference
GERMANTOWN, Md., Aug. 3, 2018 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced Robert Walsh, Senior Vice President, Energy and Fine Chemicals Platforms, will present at the Jefferies 2018 Global Industrials Conference in New York City on Tuesday, August 7, 2018 at 8:00 am Eastern. Mr. Walsh's presentations will highlight Intrexon's proprietary methane bioconversion platform to convert natural gas into high-value fuels and chemicals through microbial fermentat...
Aug 02, 2018 03:30 am ET
Intrexon to Announce Second Quarter and First Half 2018 Financial Results on August 9th
GERMANTOWN, Md., Aug. 2, 2018 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced it will release second quarter and first half 2018 financial results after the market closes on Thursday, August 9th, 2018.  The Company will host a conference call that day at 5:30 PM ET to discuss the results and provide a general business update....
Jul 31, 2018 03:45 am ET
Ziopharm Oncology to Announce Second Quarter 2018 Financial Results, Host Conference Call Aug. 8
Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today announced that management will host a conference call and webcast slide presentation on Wednesday, Aug. 8, at 4:30 p.m. ET to provide a corporate update and discuss financial results for the second...
Jul 26, 2018 08:05 am ET
Ziopharm Oncology Board Responds to Recent Stock Price Decline
Ziopharm Oncology, Inc. (Nasdaq:ZIOP), a biotechnology company focused on development of next generation immunotherapies utilizing gene- and cell-based therapies to treat patients with cancer, today responded to the recent stock price decline and...
Jun 29, 2018 02:00 am ET
Intrexon Announces Pricing of Offerings of Convertible Senior Notes and Common Stock
GERMANTOWN, Md., June 29, 2018 /PRNewswire/ -- Intrexon Corporation (NYSE: XON) (the "Company") today announced that it has priced its offering of $200.0 million aggregate principal amount of its 3.50% Convertible Senior Notes due 2023 (the "Notes") in an underwritten offering registered with the Securities and Exchange Commission (the "SEC")....
Jun 28, 2018 12:01 pm ET
Ziopharm Oncology Enrolls First Patient in Phase 1 Trial Evaluating Combination Therapy of Controlled IL-12 and OPDIVO®
Ziopharm Oncology, Inc. (Nasdaq:ZIOP), a biotechnology company focused on development of next generation immunotherapies utilizing gene- and cell-based therapies to treat patients with cancer, today announced that it has enrolled the first patient...
Jun 27, 2018 12:47 pm ET
Intrexon Announces Proposed Offerings of Convertible Senior Notes and Common Stock
GERMANTOWN, Md., June 27, 2018 /PRNewswire/ -- Intrexon Corporation (NYSE: XON) (the "Company") today announced that it intends to offer and sell, subject to market and other conditions, $200.0 million aggregate principal amount of its Convertible Senior Notes due 2023 (the "Notes") in an underwritten offering registered with the Securities and Exchange Commission (the "SEC").  The Company expects to grant the underwriters of the Notes a 30-day option to purchase up to an additional $30.0 million aggregate principal amount of Notes, solely to cover over-allotments, if any....
Jun 19, 2018 05:44 am ET
Jun 18, 2018 03:30 am ET
Ziopharm Oncology Reports on Status of Investigational New Drug Application for Phase 1 Trial to Evaluate CD19-targeted CAR T Therapy
Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today announced the U.S. Food and Drug Administration (FDA) placed on clinical hold a Phase 1 trial to evaluate CD19-specific CAR-T therapies manufactured under point-of-care and requested additional...
Jun 04, 2018 03:56 am ET
Ziopharm Oncology Presents Clinical Data Demonstrating Anti-tumor Immune Response of Controlled IL-12 Platform in Breast Cancer and Glioblastoma at American Society of Clinical Oncology (ASCO) Annual
Ziopharm Oncology, Inc. (Nasdaq:ZIOP), a biotechnology company focused on development of next generation immunotherapies utilizing gene- and cell-based therapies to treat patients with cancer, today presented clinical data showing the Company’s...
May 29, 2018 04:00 am ET
Isolation and Recombinant Expression of Key Enzyme for Opioid Production
BUDAPEST, Hungary, May 29, 2018 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, and Epimeron, Inc., a world-class provider of gene discovery and biosynthetic pathway optimization, today announced the isolation and recombinant expression of a novel gene from the opium poppy (Papaver somniferum) encoding the enzyme, thebaine synthase.  The existence of this enzyme is essential to increase the rate of the final step in thebaine synthesis.  This breakthrough allows biosynthesis...
May 24, 2018 03:00 am ET
May 23, 2018 04:11 am ET
The Cayman Government and Oxitec Launch Innovative Pilot to Suppress Aedes aegypti
WEST BAY, Grand Cayman, May 23, 2018 /PRNewswire/ --...
May 23, 2018 04:11 am ET
The Cayman Government and Oxitec Launch Innovative Pilot to Suppress Aedes aegypti
WEST BAY, Grand Cayman, May 23, 2018 /PRNewswire/ --...
May 21, 2018 04:00 am ET
Precigen Announces First Patient Dosed in Phase 1 Clinical Study of INXN-4001
GERMANTOWN, Md., May 21, 2018 /PRNewswire/ -- Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation and a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients, today announced the treatment of the first patient in a Phase 1 first-in-human clinical trial of its investigational therapy, INXN-4001....
May 16, 2018 01:00 pm ET
Ziopharm Oncology to Present Data from Clinical Studies of Controlled IL-12 in Breast Cancer and Glioblastoma at American Society of Clinical Oncology (ASCO) Annual Meeting
Ziopharm Oncology, Inc. (Nasdaq:ZIOP), a biotechnology company focused on development of next generation immunotherapies utilizing gene- and cell-based therapies to treat patients with cancer, today announced that clinical data showing the...
May 16, 2018 03:45 am ET
Recent Analysis Shows H&R Block, Opko Health, Geron, Cardinal Health, Corning, and Intrexon Market Influences — Renewed Outlook, Key Drivers of Growth
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of H Block, Inc. (NYSE:HRB), Opko Health, Inc. (NASDAQ:OPK), Geron...
May 14, 2018 04:00 am ET
Intrexon to Participate in the Bank of America Merrill Lynch 2018 Healthcare Conference
GERMANTOWN, Md., May 14, 2018 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced Lt. General (Ret.) Thomas P. Bostick, PhD, PE, Dist.M. ASCE, NAE, Intrexon's Chief Operating Officer, and Thomas E. Shrader, PhD, CFA, Vice President, Communications and Strategy, will participate in a fireside chat session at the Bank of America Merrill Lynch 2018 Healthcare Conference at Encore at the Wynn, Las Vegas, Nevada on Tuesday, May 15th, at 5:00 p.m. Pacific Time.  ...
May 10, 2018 12:05 pm ET
Intrexon Announces First Quarter 2018 Financial Results
GERMANTOWN, Md., May 10, 2018 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced its first quarter financial results for 2018. ...
May 10, 2018 12:01 pm ET
Ziopharm Oncology Reports First Quarter 2018 Financial Results and Provides Corporate Update
Ziopharm Oncology, Inc. (Nasdaq:ZIOP), today announced financial results for the first quarter ended March 31, 2018, and provided an update on the Company’s recent activities. “The landscapes of CAR-T therapies and the use of cytokines are...
May 08, 2018 12:45 pm ET
AquaBounty Technologies, Inc. Results for the quarter ended March 31, 2018
AquaBounty Technologies, Inc. (NASDAQ:AQB) (“AquaBounty” or the “Company”), a biotechnology company focused on enhancing productivity in the aquaculture market and a majority-owned subsidiary of Intrexon Corporation (NYSE:XON), announces the...
May 03, 2018 04:00 am ET
Intrexon to Announce First Quarter 2018 Financial Results on May 10th
GERMANTOWN, Md., May 3, 2018 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced it will release first quarter 2018 financial results after the market closes on Thursday, May 10th, 2018.  The Company will host a conference call that day at 5:30 PM ET to discuss the results and provide a general business update....
May 02, 2018 03:57 am ET
Ziopharm Oncology to Announce First Quarter 2018 Financial Results, Host Conference Call May 10
BOSTON, May 02, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP), today announced that management will host a conference call and webcast slide presentation on Thursday, May 10, at 4:30 p.m. ET to provide a corporate update and...
Apr 27, 2018 07:15 am ET
AquaBounty Technologies, Inc. Announces FDA Approval of First U.S. Facility for Commercial Production of AquAdvantage Salmon
MAYNARD, Mass., April 27, 2018 (GLOBE NEWSWIRE) -- AquaBounty Technologies, Inc. (Nasdaq:AQB) (“AquaBounty” or the “Company”), a biotechnology company focused on enhancing productivity in the aquaculture market and a majority-owned subsidiary of Intrexon Corporation (NYSE:XON), today announces that...
Apr 16, 2018 03:00 am ET
Exemplar Genetics Rare Neurological Disease Model Cleared by FDA for Commercial Research Use
SIOUX CENTER, Iowa, April 16, 2018 /PRNewswire/ -- Exemplar Genetics, a wholly owned subsidiary of Intrexon Corporation (NYSE: XON) committed to enabling the study of life-threatening human diseases, today announced the U.S. Food & Drug Administration (FDA) has exercised enforcement discretion in regard to the ExeGen®ATM MiniSwine model clearing it for commercial use as a research model. The ExeGen®ATM MiniSwine is genetically engineered (GE) to model ataxia telangiectasia (AT), a rare, inherited, predominantly neurological human disease.  Exemplar has previously received approval for it...
Mar 29, 2018 05:25 am ET
ActoBio Therapeutics Greenlighted by FDA to Commence a Phase Ib/IIa Trial with AG019 for the Treatment of Early Onset Type 1 Diabetes
GHENT, Belgium, March 29, 2018 /PRNewswire/ -- ActoBio Therapeutics, a wholly owned subsidiary of Intrexon Corporation (NYSE: XON) and innovative biotechnology company focused on a new class of orally delivered biopharmaceuticals, and Intrexon T1D Partners LLC, have been granted allowance by the U.S. Food and Drug Administration (FDA) for their Investigational New Drug (IND) application to initiate a Phase Ib/IIa study for the treatment of early onset type 1 diabetes (T1D) with AG019, an innovative disease-modifying approach to induce immune tolerance in T1D.  Currently no disease-modifying ...
Mar 13, 2018 05:00 am ET
Newman Ferrara LLP Announces Corporate Governance Investigation of Intrexon Corporation - XON
Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Intrexon Corporation (“Intrexon” or the “Company”) (NYSE:XON) focusing on potential breaches of fiduciary duty by the Company’s Board of Directors (the “Board”).
Mar 08, 2018 11:30 am ET
AquaBounty Technologies, Inc. Results for the year ended December 31, 2017
MAYNARD, Mass., March 08, 2018 (GLOBE NEWSWIRE) -- AquaBounty Technologies, Inc. (NASDAQ:AQB) (“AquaBounty” or the “Company”), a biotechnology company focused on enhancing productivity in the aquaculture market and a majority-owned subsidiary of Intrexon Corporation (NYSE:XON), announces the Company’s...
Mar 08, 2018 02:40 am ET
Detailed Research: Economic Perspectives on Cardtronics, Helix Energy, Plains Group Holdings, Vista Outdoor, Intrexon, and Zimmer Biomet — What Drives Growth in Today's Competitive Landscape
NEW YORK, March 08, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cardtronics PLC (NASDAQ:CATM), Helix Energy Solutions...
Mar 01, 2018 11:01 am ET
Mar 01, 2018 10:05 am ET
Intrexon Announces Fourth Quarter and Full Year 2017 Financial Results
GERMANTOWN, Md., March 1, 2018 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced its fourth quarter and full year financial results for 2017. ...
Feb 22, 2018 02:00 am ET
Intrexon to Announce Fourth Quarter and Full Year 2017 Financial Results on March 1st
GERMANTOWN, Md., Feb. 22, 2018 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced it will release fourth quarter and full year 2017 financial results after the market closes on Thursday, March 1st, 2018.  The Company will host a conference call that day at 5:30 PM ET to discuss the results and provide a general business update....
Feb 13, 2018 02:15 am ET
Ziopharm Oncology to Announce Fourth Quarter and Full Year 2017 Year-end Financial Results and Host Conference Call on March 1
BOSTON, Feb. 13, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP), today announced that management will host a conference call and webcast slide presentation on Thursday, March 1, at 4:30 p.m. ET to provide a corporate update and...
Feb 12, 2018 02:00 am ET
Ziopharm Oncology Presents Data on Very Rapid Production of CAR T Cells at Keystone Symposia Emerging Cellular Therapies: T Cells and Beyond
Human CAR+ T cells with membrane-bound IL-15 manufactured in less than two days exhibited anti-tumor activity and persistence in pre-clinical studies
Feb 06, 2018 03:55 am ET
Ziopharm Oncology Addresses Rumors and Stock Volatility, Affirms 2018 Guidance
BOSTON, Feb. 06, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today responded to unfounded rumors regarding possible financing plans of the Company. Management states that it knows of no developments at the Company that would be the...
Jan 30, 2018 03:00 am ET
Fibrocell Announces FDA Allowance to Initiate Pediatric Enrollment in Phase 1/2 Clinical Trial of FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
EXTON, Pa., Jan. 30, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue, today announced that it obtained allowance from the U.S. Food and...
Jan 19, 2018 04:41 am ET
Intrexon Announces Closing of Public Offering of Common Stock and Exercise of Option by Underwriters
GERMANTOWN, Md., Jan. 19, 2018 /PRNewswire/ -- Intrexon Corporation (NYSE: XON) announced today the closing of its previously announced underwritten public offering of common stock. Intrexon sold 6,900,000 shares of its common stock at a public offering price of $12.50 per share, including the exercise in full by the underwriters of their option to purchase an additional 900,000 shares of common stock.  Gross proceeds to Intrexon from the offering are expected to be approximately $86 million before deducting the underwriting discount and other offering expenses payable by Intrexon....
Jan 17, 2018 03:16 am ET
Intrexon Prices Public Offering of Common Stock
GERMANTOWN, Md., Jan. 17, 2018 /PRNewswire/ -- Intrexon Corporation (NYSE: XON) announced today that it has priced its previously announced underwritten public offering of common stock consisting of 6,000,000 shares at a public offering price of $12.50 per share. In addition, Intrexon has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock offered in the public offering. ...
Jan 16, 2018 10:15 am ET
Intrexon Announces Proposed Public Offering of Common Stock
GERMANTOWN, Md., Jan. 16, 2018 /PRNewswire/ -- Intrexon Corporation (NYSE: XON) announced today it has commenced an underwritten public offering of shares of its common stock. In addition, Intrexon intends to grant the underwriters a 30-day option to purchase additional shares of its common stock.  The offering is subject to market and other conditions and there can be no assurances as to whether or when the offering may be completed, or as to the size or terms of the offering....
Jan 12, 2018 04:20 am ET
AquaBounty Technologies, Inc. Announces $12 Million Underwritten Public Offering
MAYNARD, Mass., Jan. 12, 2018 (GLOBE NEWSWIRE) -- AquaBounty Technologies, Inc. (Nasdaq:AQB) (“AquaBounty” or the “Company”), a biotechnology company focused on enhancing productivity in the aquaculture market and a majority-owned subsidiary of Intrexon Corporation (NYSE:XON), today announced that it...
Jan 09, 2018 02:00 am ET
Ziopharm Oncology Provides Update on Standout Technologies during the 36th Annual J.P. Morgan Healthcare Conference
- Controlled IL-12 advancing as drug platform as monotherapy and in combination with OPDIVO® (nivolumab) -- Non-viral T-cell platform shows potential for efficacy, scalability and cost reduction for multiple oncology targets -
Jan 04, 2018 02:35 am ET
Intrexon's ActoBio Therapeutics to Present at Biotech Showcase 2018 on January 8
GHENT, Belgium, Jan. 4, 2018 /PRNewswire/ -- ActoBio Therapeutics, Inc., a wholly owned subsidiary of Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced that Pieter Rottiers, PhD, ActoBio's Chief Executive Officer, will present at the Biotech Showcase 2018 Conference in San Francisco on Monday, January 8th at 2 p.m. Pacific Time.  The presentation will highlight the innovative, proprietary ActoBiotics® drug delivery platform for oral and topical administration of biologicals t...
Jan 04, 2018 02:30 am ET
Intrexon to Present at the 36th Annual J.P. Morgan Healthcare Conference
GERMANTOWN, Md., Jan. 4, 2018 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced that Randal J. Kirk, Chairman and Chief Executive Officer will present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 10th at 9:30 a.m. Pacific Time....
Jan 02, 2018 02:00 am ET
Intrexon Corporation Annual CEO Letter
GERMANTOWN, Md., Jan. 2, 2018 /PRNewswire/ -- Randal J. Kirk, Chairman and Chief Executive Officer of Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, sent the following annual letter to his colleagues at Intrexon....
Dec 21, 2017 11:05 am ET
ZIOPHARM to Present at the 36th Annual J.P. Morgan Healthcare Conference
BOSTON, Dec. 21, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January...
Dec 10, 2017 12:00 pm ET
ZIOPHARM Announces Presentation of Data from T-Cell Therapy Programs at ASH Annual Meeting
– Clinical data show continued survival benefit, tumor response, and multi-year persistence of Sleeping Beauty-modified CD19-specific CAR+ T cells –– Point-of-care CD19-specific CAR+ T cells co-expressing mbIL15 with control switch show sustained persistence, anti-tumor effect in preclinical models without the...
Nov 27, 2017 03:20 am ET
Report: Developing Opportunities within Social Reality, The Finish Line, Facebook, Organovo, Plug Power, and Intrexon — Future Expectations, Projections Moving into 2018
NEW YORK, Nov. 27, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Social Reality Inc. (NASDAQ:SRAX), The Finish...
Nov 27, 2017 02:00 am ET
Intrexon Announces Key Management Appointments
GERMANTOWN, Md., Nov. 27, 2017 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology, today announced key executive promotions: ...
Nov 20, 2017 02:00 am ET
ZIOPHARM Presents Positive Updated Results of Ad-RTS-hIL-12 Study in Brain Cancer at Society for Neuro-Oncology Annual Meeting
– Controlled IL-12 gene therapy turns cold tumors hot –– MRI indicates decreasing size of brain tumor lesions in several patients –– Median overall survival for patients with recurrent glioblastoma (rGBM) maintained at 12.5 months in 20mg cohort with longer...
Nov 16, 2017 02:00 am ET
AquaBounty wins Gold Leaf Award for Best “Emerging Agriculture Company” from BIOTECanada
MAYNARD, Mass., Nov. 16, 2017 (GLOBE NEWSWIRE) -- AquaBounty Technologies, Inc. (NASDAQ:AQB), a biotechnology company focused on enhancing productivity in the aquaculture market and a majority-owned subsidiary of Intrexon Corporation (NYSE:XON), has won the Gold Leaf Award –...
Nov 10, 2017 11:05 am ET
ZIOPHARM to Present at the Stifel 2017 Healthcare Conference
BOSTON, Nov. 10, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that David Mauney, M.D., CBO and interim COO, will present at the Stifel 2017 Healthcare Conference in New York on Tuesday, November 14, 2017 at 11:00 a.m. ET....
Nov 10, 2017 11:05 am ET
ZIOPHARM to Present at the Stifel 2017 Healthcare Conference
BOSTON, Nov. 10, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that David Mauney, M.D., CBO and interim COO, will present at the Stifel 2017 Healthcare Conference in New York on Tuesday, November 14, 2017 at...
Nov 10, 2017 03:00 am ET
Intrexon to Present at the Stifel 2017 Healthcare Conference
GERMANTOWN, Md., Nov. 10, 2017 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced that Randal J. Kirk, Chairman and Chief Executive Officer of Intrexon, will present at the Stifel 2017 Healthcare Conference at the Lotte New York Palace Hotel in New York on Tuesday, November 14th at 10:15 a.m. Eastern Time....
Nov 09, 2017 11:05 am ET
Intrexon Announces Third Quarter 2017 Financial Results
GERMANTOWN, Md., Nov. 9, 2017 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced its third quarter financial results for 2017. ...
Nov 06, 2017 11:05 am ET
ZIOPHARM Oncology Reports Third Quarter 2017 Financial Results and Provides Update on Recent Activities
Company to host conference call today at 4:30 p.m. ETPivotal, randomized control trial in rGBM to initiate by end of 2017Combination trial with checkpoint inhibitor in rGBM to initiate by end of 2017Point-of-care trial with CAR+ T cells co-expressing membrane-bound interleukin (mbIL15) to initiate in 2018 BOSTON, Nov. 06, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company developing new gene and cell-based immunotherapies for cancer, today announced its financial results for the third quarter ended Sept. 30, 2017, and provided an update on plans to i...
Nov 06, 2017 11:05 am ET
ZIOPHARM Oncology Reports Third Quarter 2017 Financial Results and Provides Update on Recent Activities
BOSTON, Nov. 06, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company developing new gene and cell-based immunotherapies for cancer, today announced its financial results for the third quarter ended Sept. 30, 2017, and provided an...
Nov 06, 2017 02:00 am ET
ZIOPHARM Announces Four Presentation Abstracts at the 2017 Annual Meeting of the Society for Neuro-Oncology
- Update to survival data from Phase 1 Trial of Ad-RTS-hIL-12 to treat recurrent glioblastoma (GBM) to be presented -
Nov 02, 2017 12:30 pm ET
AquaBounty Technologies, Inc. Results for the quarter ended September 30, 2017
MAYNARD, Mass., Nov. 02, 2017 (GLOBE NEWSWIRE) -- AquaBounty Technologies, Inc. (NASDAQ:AQB) (“AquaBounty” or the “Company”), a biotechnology company focused on enhancing productivity in the aquaculture market and a majority-owned subsidiary of Intrexon Corporation (NYSE:XON), announces the Company’s financial results for the quarter ended September 30, 2017....
Nov 02, 2017 12:30 pm ET
AquaBounty Technologies, Inc. Results for the quarter ended September 30, 2017
MAYNARD, Mass., Nov. 02, 2017 (GLOBE NEWSWIRE) -- AquaBounty Technologies, Inc. (NASDAQ:AQB) (“AquaBounty” or the “Company”), a biotechnology company focused on enhancing productivity in the aquaculture market and a majority-owned subsidiary of Intrexon Corporation (NYSE:XON), announces the Company’s...
Nov 01, 2017 05:37 am ET
ZIOPHARM Announces Five Abstracts Accepted for Presentation at the 2017 American Society of Hematology Annual Meeting
BOSTON, Nov. 01, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on developing gene and cell-based immunotherapies for cancer, today announced that five abstracts highlighting data from the Company’s adoptive cell-based therapeutic programs have...
Nov 01, 2017 05:00 am ET
Intrexon to Announce Third Quarter 2017 Financial Results on November 9th
GERMANTOWN, Md., Nov. 1, 2017 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced it will release third quarter 2017 financial results after the market closes on Thursday, November 9th, 2017.  The Company will host a conference call that day at 5:30 PM ET to discuss the results and provide a general business update....
Oct 31, 2017 03:30 am ET
Agilis Biotherapeutics Announces Orphan Product Designation Approval in Europe for the Treatment of Friedreich Ataxia
Agilis Biotherapeutics, Inc. (Agilis), a biotechnology company advancing innovative DNA therapeutics for rare genetic diseases that affect the central nervous system (CNS), announced today that the European Commission (EC) has granted Orphan Medicinal Product (OMP) designation in the European Union (EU) to the Company’s gene therapy produ
Oct 23, 2017 05:00 am ET
Intrexon and Arch Pharmalabs Collaborate on Fermentative Production of an API to Replace Existing Process Sourced from Animals
BUDAPEST, Hungary, Oct. 23, 2017 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, and Arch Pharmalabs Ltd., a world-class provider of small molecule process chemistry and full life-cycle active pharmaceutical ingredients (API), today announced they have entered into an exclusive collaboration to develop microbial strains for fermentation-based production of an API currently sourced from animals.  ...
Oct 19, 2017 05:00 am ET
Intrexon CEO to Participate in World Food Prize Leadership Panel on Global Hunger
GERMANTOWN, Md., Oct.19, 2017 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced that Randal J. Kirk, Chairman and Chief Executive Officer, will participate in a CEO panel titled "Consolidation, Innovation, and the Road to Feeding 9 Billion by 2050" at the Borlaug Dialogue on October 19th at 3:15 pm CT....
Oct 16, 2017 01:13 pm ET
Intrexon Corporation Enters into $100 Million Preferred Stock Equity Facility
GERMANTOWN, Md., Oct. 16, 2017 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced that it has entered into a Preferred Stock Equity Facility with an affiliate of Third Security, LLC, a venture capital firm founded by Randal J. Kirk, Intrexon's Chairman and Chief Executive Officer ("Investor").  Under the facility, Intrexon may, at its discretion, sell to the Investor up to $100 million of newly issued Series A Redeemable Preferred Stock.  Any such preferred sto...
Oct 16, 2017 05:00 am ET
Intrexon Crop Protection Achieves Milestone in Development of Pioneering Self-Limiting Fall Armyworm Solution
OXFORD, England, Oct. 16, 2017 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced the achievement of a key milestone in the development of its innovative solution for control of the agricultural pest fall armyworm (Spodoptera frugiperda) in collaboration with a leading agricultural company.  Intrexon Crop Protection's targeted, biologically-based approach utilizing Oxitec's self-limiting insect technology holds substantial promise to control this major agricult...
Oct 11, 2017 05:41 am ET
Oxitec do Brasil Receives Prestigious Award for Innovation and Impact
PIRACICABA, Brazil, October 11, 2017 /PRNewswire/ --...
Oct 04, 2017 10:00 am ET
Oct 02, 2017 12:30 pm ET
Fibrocell to Present at 2017 Cell & Gene Meeting on the Mesa
EXTON, Pa., Oct. 02, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc., (NASDAQ:FCSC) today announced that John Maslowski, President and Chief Executive Officer of Fibrocell, will present at 3:00 pm PDT on Wednesday, October 4 at the annual Partnering Forum, part of the Cell & Gene Meeting on the Mesa to be held October 4-6 in La Jolla, California. Mr. Maslowski will discuss the interim results of Fibrocell’s Phase 1/2 clinical trial of FCX-007 for the treatment of recessive dystrophic epidermolysis bullosa....
Sep 26, 2017 04:00 am ET
Fibrocell Reports Interim Results of Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
– FCX-007 well-tolerated through 12 weeks post-administration with encouraging safety and positive early trends noted in wound healing and pharmacology signals –...
Sep 19, 2017 08:00 am ET
Oxitec to Build State-of-the-Art Mosquito Egg Production Unit
OXFORD, England, September 19, 2017 /PRNewswire/ --...
Sep 18, 2017 04:00 am ET
ZIOPHARM Oncology Announces Updated Findings from Phase 1 Study of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma Presented at American Academy of Neurological Surgery Annual Meeting
BOSTON, Sept. 18, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new immunotherapies, today announced that updated data from a subset of patients in its Phase 1 multicenter study of Ad-RTS-hIL-12 + veledimex in patients with recurrent or progressive glioblastoma (GBM) was presented at the 79th Annual Meeting of the American Academy of Neurological Surgery (AANS) in Santa Barbara, CA. Ad-RTS-hIL-12 + veledimex is ZIOPHARM’s adenoviral (Ad) gene therapy candidate for the controlled expression of human interleukin-12 (hIL-12), a critical p...
Sep 05, 2017 12:00 am ET
Aug 31, 2017 01:01 pm ET
Intrexon to Participate in Upcoming Investor Conferences
GERMANTOWN, Md., Aug. 31, 2017 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced that Andrew Last, Ph.D., Chief Operating Officer, will participate in the following upcoming investor conferences:...
Aug 11, 2017 06:31 am ET
Covered Call reports for American Airlines, Hawaiian Holdings, Copa Holdings, Pan American Silver Corp and Intrexon include trade ideas that offer returns of 23% or more!
CHICAGO, Aug. 11, 2017 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAL, CPA, HA, PAAS, and XON....
Aug 09, 2017 01:05 pm ET
Intrexon Announces Second Quarter and First Half 2017 Financial Results
GERMANTOWN, Md., Aug. 9, 2017 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced its second quarter and first half financial results for 2017. ...
Aug 02, 2017 05:00 am ET
Intrexon to Announce Second Quarter and First Half 2017 Financial Results on August 9th
GERMANTOWN, Md., Aug. 2, 2017 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced it will release second quarter and first half 2017 financial results after the market closes on Wednesday, August 9th, 2017.  The Company will host a conference call that day at 5:30 PM ET to discuss the results and provide a general business update....
Jul 31, 2017 12:05 pm ET
ZIOPHARM Oncology Reports Second Quarter 2017 Financial Results and Provides Update on Recent Activities
BOSTON, July 31, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new immunotherapies, today announced its financial results for the second quarter ended June 30, 2017, and provided an update on the Company's recent activities....
Jul 11, 2017 07:00 am ET
Oxitec Launching Friendly™ Aedes Project in Juiz de Fora, Brazil
OXFORD, England, July 11, 2017 /PRNewswire/ --...
Jul 06, 2017 05:30 am ET
Oxitec's Friendly™ Aedes Mosquito Receives Positive Evaluation for European Standard in relation to Human Health and the Environment
OXFORD, England, July 6, 2017 /PRNewswire/ -- The National Institute of Public Health and the Environment (RIVM) in the Netherlands today published its "Technical evaluation of a potential release of OX513A Aedes aegypti mosquitoes on the island of Saba", which positively concludes a vector control program using Oxitec's Friendly™ Aedes aegypti mosquitoes would pose negligible risks to human health and the environment....
Jun 29, 2017 12:30 pm ET
Intrexon Appoints Helen Sabzevari, Ph.D., Senior Vice President, Human Therapeutics and Head of Research and Development of Precigen
GERMANTOWN, Md., June 29, 2017 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced the appointment of Helen Sabzevari, Ph.D., Senior Vice President, Intrexon Health Therapeutics as well as Head of Research and Development of Precigen Inc.  She will report directly to Randal J. Kirk, Chief Executive Officer of Intrexon....
Jun 16, 2017 06:15 am ET
Intrexon Integrates Leading Adenoviral Gene Delivery Technology with Completion of GenVec Acquisition
GERMANTOWN, Md., June 16, 2017 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced that it has completed the acquisition of GenVec, Inc. (NASDAQ: GNVC), a clinical-stage biopharmaceutical company and pioneer in the development of AdenoVerse™ gene delivery technology platform.  ...
Jun 13, 2017 04:00 am ET
AquaBounty Acquires Fish Farming Facility in Indiana
MAYNARD, Mass., June 13, 2017 /PRNewswire/ -- AquaBounty Technologies, Inc. (NASDAQ: AQB) ("AquaBounty" or the "Company"), a biotechnology company focused on enhancing productivity in the aquaculture market and a majority-owned subsidiary of Intrexon Corporation (NYSE: XON), announces that it has entered into an agreement to purchase certain assets of Bell Fish Company, including its farming facility in Albany, Indiana, for $14.0 million in cash....
Jun 13, 2017 04:00 am ET
Intrexon and Johnson Matthey Collaborate on Fermentative Production of Peptide-based Active Pharmaceutical Ingredients
BUDAPEST, Hungary, June 13, 2017 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, and Johnson Matthey (LN: JMAT), a global leader in science that enables cleaner air, improved health and more efficient use of natural resources, today announced they have entered into an exclusive collaboration focused on the development of microbial strains for fermentative production of peptide-based active pharmaceutical ingredients (APIs).    ...
May 24, 2017 05:00 am ET
Intrexon to Present at Upcoming Investor and Industry Conferences
GERMANTOWN, Md., May 24, 2017 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced management will present at the following upcoming investor and industry conferences: ...
May 18, 2017 01:01 pm ET
Intrexon Appoints Dr. Mark Carnegie-Brown as CEO of Oxitec
GERMANTOWN, Md., May 18, 2017 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced the appointment of Mark Carnegie-Brown, Ph.D. as Chief Executive Officer of its wholly owned subsidiary Oxitec Ltd.  Dr. Carnegie-Brown succeeds Hadyn Parry, who has been appointed Vice President, Corporate Development Europe, the Middle East, and Africa (EMEA) for Intrexon to strengthen its management ranks abroad as it continues to expand its global presence. ...
May 17, 2017 01:15 pm ET
ZIOPHARM Oncology Announces Results of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma to be Presented at the 2017 ASCO Annual Meeting
BOSTON, May 17, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new immunotherapies, today announced that it will present updated results from its Phase 1, multicenter, dose-escalation study and 20-mg expansion cohort of Ad-RTS-hIL-12 + orally administered veledimex in patients with recurrent or progressive glioblastoma (GBM) at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting to be held June 2-6 in Chicago. Ad-RTS-hIL-12 + veledimex is a novel, viral gene therapy candidate for the controlled expression of interleuk...
May 15, 2017 05:00 am ET
Intrexon to Present at the Bank of America Merrill Lynch 2017 Healthcare Conference
GERMANTOWN, Md., May 15, 2017 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced management will participate at the Bank of America Merrill Lynch 2017 Healthcare Conference at Encore at the Wynn, Las Vegas, Nevada.  ...
May 10, 2017 01:05 pm ET
Intrexon Announces First Quarter 2017 Financial Results
GERMANTOWN, Md., May 10, 2017 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced its first quarter financial results for 2017. ...
May 10, 2017 05:00 am ET
Intrexon and Darling to Build Commercial-scale Production of Insect-Based Advanced Feed Ingredients
DAVIS, Calif. and IRVING, Texas and YELLOW SPRINGS, Ohio, May 10, 2017 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, and Darling Ingredients Inc. (NYSE: DAR), the world's largest publicly-traded developer and producer of sustainable natural ingredients from bio-nutrients, today announced their joint venture EnviroFlight, LLC plans to significantly expand production of advanced ingredients for sustainable feed and nutrition derived from black soldier fly (BSF) larvae throu...
May 10, 2017 04:00 am ET
Fibrocell Reports First Quarter 2017 Financial Results and Recent Operational Highlights
EXTON, Pa., May 10, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today reported financial results for the first quarter ended March 31, 2017 and recent operational highlights. Fibrocell will host a conference call and webcast today at 8:30 a.m. EDT....
May 09, 2017 05:00 am ET
Huvepharma to Utilize Intrexon's Proprietary Fungal Expression Platform to Produce Key Animal Feed Enzyme
SOFIA, Bulgaria and BUDAPEST, Hungary, May 9, 2017 /PRNewswire/ -- Huvepharma EOOD, a global pharmaceutical company with a focus on developing, manufacturing, and marketing human and animal health products, and Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced they have entered into a research collaboration agreement.  The collaboration represents the first commercial application of Intrexon's proprietary fungal expression platform to produce a new animal feed enzyme develope...
May 03, 2017 05:00 am ET
Intrexon to Announce First Quarter 2017 Financial Results on May 10th
GERMANTOWN, Md., May 3, 2017 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced it will release first quarter 2017 financial results after the market closes on Wednesday, May 10th, 2017.  The Company will host a conference call that day at 4:30 PM ET to discuss the results and provide a general business update....
May 03, 2017 04:00 am ET
Fibrocell to Host Conference Call and Webcast on Wednesday, May 10, 2017 to Discuss First Quarter 2017 Financial Results and Recent Operational Highlights
EXTON, Pa., May 03, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, will report financial results for the first quarter ended March 31, 2017 and recent operational highlights on Wednesday, May 10, 2017, before the open of the U.S. financial markets.  Fibrocell will also host a conference call and webcast at 8:30 a.m. EDT on the same day to discuss its financial results and operational highlights. A question-and-answer session will follow Fibrocell’s re...
May 01, 2017 12:05 pm ET
ZIOPHARM Oncology Reports First Quarter 2017 Financial Results and Provides Update on Recent Activities
– Advancing Plans to Initiate Pivotal Study for Ad-RTS-hIL-12 + Veledimex for Treatment of Recurrent Brain Cancer –...
Apr 27, 2017 05:00 am ET
Intrexon Appoints Vinita Gupta, Leading Pharma Executive, to its Board of Directors
GERMANTOWN, Md., April 27, 2017 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced the appointment of Vinita Gupta to its Board of Directors effective April 25, 2017.  Ms. Gupta is currently the Chief Executive Officer of Lupin Limited, a global pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs....
Apr 20, 2017 12:05 pm ET
ZIOPHARM Oncology to Present Updated Clinical Results of Gene Therapy Candidate Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma at the 2017 ASCO Annual Meeting
BOSTON, April 20, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new immunotherapies, today announced that it will present updated results from its Phase 1, multicenter, dose-escalation study of Ad-RTS-hIL-12 + orally administered veledimex in patients with recurrent or progressive glioblastoma at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting to be held June 2-6 in Chicago. Ad-RTS-hIL-12 + veledimex is a novel, viral gene therapy candidate for the controlled expression of interleukin-12 (IL-12), a pro-inflammato...
Apr 19, 2017 04:00 am ET
Synthetic Biologics Reports Preclinical Data Demonstrating SYN-005 Provides Protection from Pertussis in Neonatal Animal Study
ROCKVILLE, Md., April 19, 2017 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, today announced positive data for SYN-005, the Company's orphan drug program for the prevention and treatment of pertussis (whooping cough). SYN-005 combines two highly synergistic humanized monoclonal antibodies (hu1B7 and hu11E6) to target and potentially inactivate the life-threatening pertussis toxin that causes disease symptoms....
Apr 10, 2017 04:00 am ET
Mar 27, 2017 04:00 am ET
ZIOPHARM Announces Successful End-of-Phase 2 Meeting with FDA for Ad-RTS-hIL-12 Gene Therapy in Recurrent Glioblastoma
BOSTON, March 27, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new immunotherapies, today announced the receipt of positive guidance from an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for its lead gene therapy product candidate, Ad-RTS-hIL-12 plus orally administered veledimex (V), to harness and control IL-12 production for the investigational treatment of recurrent glioblastoma (GBM), an aggressive form of brain cancer with few treatment options....
Mar 17, 2017 04:00 am ET
Jorge Espanha Appointed General Manager of Oxitec do Brasil
OXFORD, England, March 17, 2017 /PRNewswire/ --...
Mar 16, 2017 12:00 am ET
AquaBounty Technologies, Inc. Results for the year ended December 31, 2016
MAYNARD, Mass., March 16, 2017 /PRNewswire/ -- AquaBounty Technologies, Inc. (NASDAQ: AQB; AIM: ABTU) ("AquaBounty" or the "Company"), a biotechnology company focused on enhancing productivity in the aquaculture market and a majority-owned subsidiary of Intrexon Corporation (NYSE: XON), announces the Company's financial results for the year ended December 31, 2016....
Mar 10, 2017 11:15 am ET
Intrexon Creates Precigen, Inc. and Accelerates Strategic Review of Structural Options Related to Health Assets
GERMANTOWN, Md., March 10, 2017 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced the formation of Precigen, Inc., a wholly-owned subsidiary of the Company as part of an ongoing evaluation of structural alternatives concerning its business in healthcare.  Intrexon currently intends to consolidate all health-related assets under this new corporate entity as it considers potential strategic options to enhance shareholder value....
Mar 07, 2017 12:15 pm ET
Fibrocell to Host Conference Call and Webcast on Thursday, March 9, 2017 to Discuss 2016 Financial Results and Recent Operational Highlights
EXTON, Pa., March 07, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, will report financial results for the year ended December 31, 2016 and recent operational highlights on Thursday, March 9, 2017, before the open of the U.S. financial markets.  Fibrocell will also host a conference call and webcast at 8:30 a.m. EST on the same day to discuss its financial results and operational highlights. A question-and-answer session will follow Fibrocell’s remarks....
Mar 07, 2017 11:54 am ET
Fibrocell Announces Convertible Preferred Stock Financing for $8.0 Million
EXTON, Pa., March 07, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that it has entered into a securities purchase agreement with certain of its existing investors for the sale of $8.0 million of the Company’s Series A Convertible Preferred Stock (Preferred Stock) and accompanying common stock warrants (Warrants)....
Mar 06, 2017 04:00 am ET
Andy Bass to Lead Biological & Popular Culture, Intrexon's Consumer Sector
SAN DIEGO, March 6, 2017 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced the appointment of Andy Bass as Senior Vice President, Consumer Sector, which will henceforth do business as BioPop. Andy will lead the design and commercialization of new biologically-based products and applications across consumer markets using Intrexon's powerful platforms and expertise for engineering biology....
Mar 01, 2017 12:10 pm ET
Intrexon Announces Fourth Quarter and Full Year 2016 Financial Results
GERMANTOWN, Md., March 1, 2017 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced its fourth quarter and full year financial results for 2016.  ...
Feb 22, 2017 03:00 am ET
Intrexon to Announce Fourth Quarter and Full Year 2016 Financial Results on March 1st
GERMANTOWN, Md., Feb. 22, 2017 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced it will release fourth quarter and full year 2016 financial results after the market closes on Wednesday, March 1st, 2017.  The Company will host a conference call that day at 5:30 PM ET to discuss the results and provide a general business update....
Feb 16, 2017 11:05 am ET
ZIOPHARM Reports Fourth-Quarter 2016 Financial Results and Provides Update on Recent Activities
- Company to Webcast Corporate Update Thursday, February 23, at the 2017 RBC Global Healthcare Conference -...
Feb 13, 2017 03:00 am ET
Lt. Gen. (Ret.) Thomas P. Bostick, Head of Intrexon's Environment Sector, Elected to National Academy of Engineering
GERMANTOWN, Md., Feb. 13, 2017 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced that Lt. Gen. (Ret.) Thomas P. Bostick Ph.D., P.E., Senior Vice President and Head of Intrexon's Environment Sector, has been elected to the National Academy of Engineering (NAE). Dr. Bostick was elected for development of new approaches to hurricane protection and for his leadership of the U.S. Army Corps of Engineers (USACE) and many other significant positions throughout his mi...
Feb 02, 2017 06:41 am ET
GENVEC INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of GenVec, Inc.
NEW ORLEANS, Feb. 2, 2017 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of GenVec, Inc. ("GenVec" or the "Company") (NASDAQ: GNVC) to Intrexon Corporation (NYSE: XON). Under the terms of the proposed transaction, shareholders of GenVec will receive only 0.297 shares of Intrexon for each share of GenVec that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company....
Jan 31, 2017 02:00 am ET
ZIOPHARM Utilizing Non-Viral Sleeping Beauty Platform to Rapidly Produce CAR-Expressing T cells Advancing “Point-of-Care” Approach
– First Patient Treated with Non-viral Sleeping Beauty Modified CAR-T Cells Produced in 2 Weeks...
Jan 26, 2017 03:00 am ET
Exemplar Genetics Awarded Subcontract to Advance New Therapeutic Models for Sickle Cell Disease
SIOUX CENTER, Iowa, Jan. 26, 2017 /PRNewswire/ -- Exemplar Genetics, a wholly owned subsidiary of Intrexon Corporation (NYSE: XON) committed to enabling the study of life-threatening human diseases, has been awarded a subcontract to create genetically engineered miniswine models of sickle cell disease as part of a national resource that could lead to new treatments for the disorder....
Jan 24, 2017 04:00 am ET
Intrexon to Acquire GenVec to Expand Industry-Leading Gene Delivery Platform
GERMANTOWN, Md., and GAITHERSBURG, Md., Jan. 24, 2017 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced that it has entered into a definitive agreement to acquire GenVec, Inc. (NASDAQ: GNVC), a clinical-stage company and pioneer in the development of AdenoVerse™ gene delivery technology.  ...
Jan 23, 2017 02:00 am ET
Oxitec and GBIT Announce Launch of Friendly™ Aedes Project in India
DAWALWADI, India and OXFORD, England, January 23, 2017 /PRNewswire/ --...
Jan 19, 2017 02:00 am ET
AquaBounty Announces Completion of NASDAQ Listing and Equity Subscription from Intrexon
MAYNARD, Mass., Jan. 19, 2017 /PRNewswire/ -- AquaBounty Technologies, Inc. (AIM: ABTU; NASDAQ: AQB), a biotechnology company focused on enhancing productivity in aquaculture and a majority-owned subsidiary of Intrexon Corporation (NYSE: XON), announces that it has completed the listing of its common shares on the NASDAQ Stock Market and finalized the equity subscription from Intrexon....
Jan 12, 2017 03:00 am ET
Intrexon Announces "When-Issued" Trading of AquaBounty Technologies In Connection With Special Stock Dividend of Shares
GERMANTOWN, Md., Jan. 12, 2017 /PRNewswire/ -- Intrexon Corporation (NYSE: XON)("Intrexon" or the "Company"), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced that, in connection with the previously announced special stock dividend of 1,776,557 shares of AquaBounty Technologies, Inc. ("AquaBounty") common stock (after taking into account the 1:30 reverse stock split of AquaBounty common stock) (the "Distribution"), shares of AquaBounty common stock ex-distribution began trading January 9, 2017, under the sym...
Jan 10, 2017 03:00 am ET
ZIOPHARM and Intrexon Announce Cooperative Research and Development Agreement with the National Cancer Institute Utilizing Sleeping Beauty System to Generate T cells Targeting Neoantigens
BOSTON and GERMANTOWN, Md., Jan. 10, 2017 /PRNewswire/ -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new immunotherapies, and Intrexon Corporation (NYSE:XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced the signing of a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) for the development of adoptive cell transfer (ACT)-based immunotherapies genetically modified using the Sleeping Beauty (SB) transposon/transposase system t...
Jan 05, 2017 03:00 am ET
Fibrocell Announces FDA Fast Track Designation of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa
EXTON, Pa., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that the U. S. Food and Drug Administration (FDA) has granted Fast Track designation to FCX-007, the Company’s clinical-stage candidate for the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)—a rare, devastating genetic skin disease for which no FDA-approved therapies exist....
Jan 03, 2017 03:00 am ET
Intrexon to Present at the 35th Annual J.P. Morgan Healthcare Conference
GERMANTOWN, Md., Jan. 3, 2017 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced that Geno Germano, President of Intrexon, will present at the 35th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11th, at 9:00 a.m. Pacific Time at the Westin St. Francis in San Francisco. ...
Dec 29, 2016 03:45 am ET
Intrexon Announces a Special Stock Dividend of Shares of AquaBounty Technologies
GERMANTOWN, Md., Dec. 29, 2016 /PRNewswire/ -- Intrexon Corporation (NYSE: XON)("Intrexon" or the "Company"), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced a special stock dividend of 53,296,710 shares of common stock of AquaBounty Technologies, Inc. ("AquaBounty"), subject to adjustment to reflect a 1:30 reverse stock split of AquaBounty's common stock that is expected to be implemented by AquaBounty prior to the distribution of the special stock dividend (the "Distribution").  The Distribution is ex...
Dec 13, 2016 03:00 am ET
Intrexon Advances ActoBiotics™ Platform to Development Phase for Biological Crop Protection
DAVIS, Calif., Dec. 13, 2016 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced initial studies have validated the efficacy of dsRNA for insect control applications using its proprietary ActoBiotics™ platform.  With this achievement, Intrexon's collaboration with a leading global agricultural company advances to its next phase of development for biological crop protection solutions....
Dec 13, 2016 01:58 am ET
Synthetic Biologics Announces Granting of U.S. Composition of Matter Patent for SYN-005, Designed for the Treatment and Prevention of Pertussis (Whooping Cough)
ROCKVILLE, Md., Dec. 13, 2016 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics focused on the gut microbiome, today announced that the United States Patent Office has granted U.S. Patent No. 9,512,204 which provides composition of matter coverage for SYN-005, the Company's preclinical drug candidate designed to treat or prevent the development of Pertussis (whooping cough), especially in infants. This patent, which is co-owned with Synthetic Biologics' Pertussis academic collaborator, The University of Texas at Austin (UT Austin...
Dec 12, 2016 03:00 am ET
Oxitec's Medfly Ready for Open Field Trials
OXFORD, England, December 12, 2016 /PRNewswire/ --...
Nov 30, 2016 02:03 am ET